Wholesale distributor licensing under the DSCSA

The Drug Supply Chain Security Act gave the Food and Drug Administration two years, until November 27, 2015, to write national licensing standards for prescription drug wholesalers. The statute¹ says so in its first sentence on the subject. FDA published its proposed rule² on February 4, 2022, a little over six years late. In the HHS regulatory agenda published August 14, 2026³, the final rule is listed as a long-term action with a target date of June 2028.

Until then, wholesaler licensing works much as it has since 1990. States issue the licenses, under federal guidelines in 21 CFR part 205⁴ that were first published on September 14, 1990, and wholesalers file an annual report with FDA.

A license matters more than it sounds. Under the 2013 law, manufacturers, pharmacies and other wholesalers may only buy from or sell to "authorized" trading partners, and a wholesaler counts as authorized only if it holds a valid license and reports it to FDA. This explainer covers who has to be licensed, what the national standards would require, where the 2022 proposal stands, and what the annual FDA report contains. GxRadar's companion piece on what drug wholesalers do covers the business side.

Who needs a wholesale license

Federal licensing rules for wholesalers date to the Prescription Drug Marketing Act of 1987, which, as FDA recounts in its 2022 proposal², required wholesalers to hold licenses from the states they operated in. FDA's 1990 guidelines set minimum state standards for storage, records and personnel.

The Drug Quality and Security Act⁵, signed November 27, 2013, rewrote that framework in its Title II, the DSCSA. Section 503(e) of the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 353(e)⁶, now says no one may engage in wholesale distribution of a prescription drug unless licensed by the state the drug ships from, or by FDA if that state has no licensing program. A wholesaler shipping across state lines also needs a license from the receiving state if that state requires one.

Section 503(e) also defines wholesale distribution as distribution to anyone other than a consumer or patient, then carves out exceptions. These include transfers within one company, transfers among hospitals under common control, and distribution "for emergency medical reasons." The statute adds a pointed qualifier: "a drug shortage not caused by a public health emergency shall not constitute an emergency medical reason."

Every state and the District of Columbia appears on FDA's list of state licensing agencies⁷. The agencies vary more than most people would guess.

Counts are GxRadar's tally of FDA's table, which the agency last updated March 6, 2026.

What the national standards must cover

Congress spelled out the content. Section 583 of the act, at 21 U.S.C. 360eee-2¹, says the federal standards apply to every state and federal license and must address seven areas. The 2022 proposal filled in details for each.

Inspections need not be done by the licensing agency itself. The statute lets licensing authorities accept inspections by the home state or by an FDA-approved third-party accreditation or inspection service. In February 2026 FDA opened comment on the paperwork for these "approved organizations"⁸, one of the pieces that depends on the unfinished rule.

National standards would also limit what states can add. Section 585(b) of the act, at 21 U.S.C. 360eee-4⁹, bars state licensing requirements that are "inconsistent with, less stringent than, directly related to, or covered by" the federal ones. In announcing the proposal¹⁰, FDA said its reading was that once the rule takes effect, states "may not establish or continue licensure requirements" unless those requirements are the same as the federal ones. FDA described the current system as a "patchwork" and said that "unlicensed wholesale distributors are often involved in incidents of distributed stolen or counterfeit drugs."

Where the 2022 proposal stands

FDA's proposal would replace part 205 entirely and set up a federal licensing program for wholesalers in any state without a conforming program. FDA extended the comment period¹¹ once, to September 6, 2022.

By the agency's own economic analysis, annualized costs over 10 years would be $16.92 million and benefits $10.66 million, both primary estimates at a 7 percent discount rate. The benefits it monetized came from reduced drug diversion and fewer duplicative state license applications. For its paperwork estimates, FDA counted 1,951 wholesale distributors that would become subject to the new reporting and recordkeeping requirements.

Congress built in a delay. A final wholesale licensing rule takes effect two years after publication. If FDA hits its June 2028 target, the national standards would not apply until mid-2030, nearly 15 years after Congress's deadline for writing them.

In the meantime the law treats state licensure as sufficient. FDA's 2022 revised draft guidance on identifying trading partners¹² says that until the federal regulations take effect, FDA "will generally consider a wholesale distributor to be fully licensed for DSCSA purposes if the wholesale distributor holds a valid license under State law."

The annual report to FDA

One piece of the 2013 law has been running since January 1, 2015. Every establishment engaged in wholesale distribution must report to FDA each year the states that license it and the license numbers, the name, address and contact details of each facility, and its trade names. It must also report "significant disciplinary actions, such as the revocation or suspension" of a license.

FDA asks for the annual filing between January 1 and March 31 and wants disciplinary actions reported within 30 days of a final ruling, according to its draft question-and-answer guidance¹³. The reports go into a public FDA reporting database¹⁴, updated every business day, in which each line is one license for one facility.

FDA warns that a listing is not an approval. Reporting "does not mean the facility is licensed or approved by FDA or the facility is in compliance with applicable state and federal regulations." The agency advises buyers to check both the state licensing website and the FDA database before treating a wholesaler as an authorized trading partner.

What it means further down the chain

Patients never deal with a wholesaler, but the license check is one of the main barriers between the legitimate supply and diverted or counterfeit drugs. Pharmacies, which count as dispensers under the law, must buy only from authorized partners, and most packages they receive now carry the serialized identifier described in our piece on barcodes and serial numbers. Warehouses that store drugs without owning them fall under a separate license category, covered in our explainer on third-party logistics providers. The wider tracing system is explained in our DSCSA overview.

National licensing standards remain the largest unfinished part of the law. FDA's implementation tracker¹⁵ still lists the licensing regulations under sections 583 and 584 at the proposed-rule stage. The target has slipped before. The rule's RegInfo.gov entries show a final-rule date of May 2026 in the fall 2024 agenda, May 2027 in spring 2025 and June 2028 after that. The next agenda will show whether the latest date holds.